IP Library › Granted Patent US 9,102,733
Granted Patent B2
US 9,102,733 · App. 12/958,278 · Granted Aug 11, 2015

Anti-OX40L antibodies

Inventors: Joseph Endl (Wilhelm, DE); Elsie M. Eugui (Belmont, CA); Maria Elena Fuentes (Sunnyvale, CA); Yvo Graus (Odijk, NL); Aran Frank Labrijn (Amsterdam, NL); Martin Lanzendoerfer (Tutzing, DE); Paul Parren (Odijk, NL); Frank Rebers (Utrecht, NL); Ralf Schumacher (Penzberg, DE); Stefan Seeber (Penzberg, DE); Jan Van De Winkel (Zeist, NL); Martine Van Vugt (Houten, NL)
Assignee: Roche Palo Alto LLC
C07K16/2875C07K2317/21C07K2317/52C07K2317/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,102,733
App. No.
12/958,278
Granted
Aug 11, 2015
Kind
B2
Abstract

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

Claims (18)

1. An antibody, characterized in that said antibody binds OX40L and that the antibody comprises a variable region combination wherein

the light chain variable domain is defined by amino acid sequence SEQ ID NO:3 and the heavy chain variable domain is defined by SEQ ID NO:4.

2. The antibody of claim 1 , characterized in that said antibody contains a Fc part derived from human origin, and does not bind complement factor C1q.

3. The antibody according to claim 2 , characterized in that the antibody does not bind to human Fcγ receptors on NK cells.

4. The antibody according to claim 3 , characterized in that the antibody is a human antibody.

5. The antibody according to claim 3 , characterized in that the antibody is a chimeric or humanized antibody.

6. The antibody according to claim 2 , wherein the antibody binds to OX40L with a K D value of less than 10 −8 M.

7. The antibody according to claim 6 , wherein the K D range is between about 10 −12 to about 10 −9 M.

8. The antibody according to claim 7 , characterized in that the antibody is an antibody of human subclass IgG1, containing one or more mutations selected from PVA236, GLPSS331 and/or L234A/L235A (numbering according to EU index).

9. The antibody according to claim 7 , characterized in that the antibody is an antibody of human subclass IgG4.

10. The antibody according to claim 9 , characterized in containing mutation S228P.

11. The antibody according to claim 9 , characterized in containing mutation L235E.

12. The antibody according to claim 2 , characterized in that does not activate complement factor C3.

13. The antibody according to claim 2 , characterized in that it does not elicit complement-dependent cytotoxicity (CDC).

14. The antibody according to claim 2 , characterized in that it does not elicit antibody-dependent cellular cytotoxicity (ADCC).

15. The antibody according to claim 2 , characterized in that it shows in an ELISA assay inhibition by blocking the interaction of immobilized OX40L with soluble OX40 at a coating concentration of 0.5 μg/ml OX40L with an IC50 value in the range of 1 nM-4 nM.

16. An antibody characterized in that said antibody binds OX40L, contains a Fc part derived from human origin, and does not bind complement factor C1q, and that the human light chain variable region comprises an amino acid sequence of SEQ ID NO: 3.

17. The antibody according to claim 16 , characterized in that the human heavy chain variable region comprises an amino acid sequence SEQ ID NO:4.

Priority Claims (2)
EP 04022158 · Sep 17, 2004 · regional
EP 04030546 · Dec 23, 2004 · regional
Continuity (3)
Division 12315863 · Dec 5, 2008
Division 11229162 · Sep 16, 2005
Related Publication 20110070239A1 · Mar 24, 2011